A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Yuji MinegishiOu YamaguchiShunichi SugawaraShoichi KuyamaSatoshi WatanabeKazuhiro UsuiMasahide MoriOsamu HatajiToshihiro NukiwaSatoshi MoritaKunihiko KobayashiAkihiko GemmaPublished in: BMC cancer (2021)
The trial is registered with Japan Registry of Clinical Trials (JRCT) as trial number 031180136 (date of initial registration: 19 February 2019), and the University Hospital Network (UMIN) as trial number 000017877 (date of initial registration: 11 June 2015).
Keyphrases
- clinical trial
- phase iii
- phase ii
- advanced non small cell lung cancer
- study protocol
- phase ii study
- epidermal growth factor receptor
- open label
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- placebo controlled
- locally advanced
- radiation therapy
- patient reported outcomes
- rectal cancer